Homologation of Monoterpenoids into New Sesquiterpenoidsvia Tandem Isomerisation/Claisen Rearrangement Reactions with Three-Component Ruthenium Catalysts, and Ru(methallyl)2(COD) Revealed by High Throughput Screening Techniques

2005 ◽  
Vol 347 (6) ◽  
pp. 783-791 ◽  
Author(s):  
Jérôme Le Nôtre ◽  
Rachid Touzani ◽  
Olivier Lavastre ◽  
Christian Bruneau ◽  
Pierre H. Dixneuf
Keyword(s):  
High Throughput ◽  
High Throughput Screening ◽  
Claisen Rearrangement ◽  
Ruthenium Catalysts ◽  
Screening Techniques ◽  
Rearrangement Reactions

scholarly journals High throughput screening techniques for pre-formulation: salt selection and polymorph studies

2002 ◽  
Vol 58 (s1) ◽  
pp. c9-c9 ◽  
Author(s):  
P. Desrosiers ◽  
E. Carlson ◽  
W. Chandler ◽  
H. Chau ◽  
P. Cong ◽  
...  
Keyword(s):  
High Throughput ◽  
High Throughput Screening ◽  
Screening Techniques ◽  
Salt Selection

RNA therapies hold great promise for treating cancer. High-throughput screening techniques have facilitated the development of RNA treatments

2021 ◽  
Author(s):  
Moataz Dowaidar
Keyword(s):  
Clinical Trials ◽  
High Throughput ◽  
High Throughput Screening ◽  
Small Firms ◽  
Large Scale ◽  
Great Promise ◽  
Primary Study ◽  
Hospital System ◽  
Screening Techniques ◽  
Point Of Entry

High throughput screening techniques have facilitated the creation of RNA treatments, and these findings have been accompanied by unique modifications of RNA structures to increase stability and minimize toxicity, as well as innovative delivery systems such as LNPs. "undruggable" targets, "swiftly construct vaccinations," and to provide therapeutic approaches that can be tailored to individual patients Like the genetic code, RNA therapies hold great promise.At the same time, our hospital launched a specialized RNA Therapeutics program that assists both our internal scientists and external academic groups or small firms aiming to apply their fundamental research discoveries to innovative treatments. mRNA is primarily stable because of our primary study in sequencing and structure. For synthesis, purification, and validation of RNA constructs, we have a contemporary GMP program with clean rooms. Our company collaborates with Nanomedicine to build LNP structures that transport mRNA constructs locally and systemically. We have an opportunity to hire and integrate first-in-man clinical trials unit, as well as a big hospital system with a clinical research infrastructure that enables industry-sponsored Phase 2 and 3 clinical trials. Additionally, we have a large-scale mRNA construction industrial sponsor for Phases 2, 3, and commercialization. Essentially, we've put up a production line for universities and small firms interested in turning their mRNA creations into revolutionary medications. One hospital, one point of entry to ensure that RNA-based drugs are created and translated into the clinic efficiently. Many tiny firms with fresh concepts for disruptive mRNA therapeutics cannot reach the clinic without new translational capabilities. We think we are the only academic organization with the infrastructure to help small academic groups and biotech enterprises, and we want to aid both internal and external translational activities in the coming years.

Sign in / Sign up

Export Citation Format

Share Document